Shares of Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) shot up 3.1% on Friday . The stock traded as high as $0.15 and last traded at $0.13. 288,748 shares were traded during mid-day trading, an increase of 189% from the average session volume of 99,998 shares. The stock had previously closed at $0.13.
Bioxytran Stock Performance
The stock has a market cap of $23.05 million, a P/E ratio of -3.31 and a beta of -0.83. The business has a 50 day simple moving average of $0.12 and a 200-day simple moving average of $0.13.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($0.01) earnings per share for the quarter.
About Bioxytran
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
Recommended Stories
- Five stocks we like better than Bioxytran
- Most Volatile Stocks, What Investors Need to Know
- MarketBeat Week in Review – 4/15 – 4/19
- Using the MarketBeat Dividend Tax Calculator
- Comprehensive Analysis of PayPal Stock
- Stock Market Upgrades: What Are They?
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
